

TRIPOD Checklist: Prediction Model Development and Validation

Section	Item		Checklist description	Reported on Page Number/Line Number	Reported on Section/Paragraph
Title and abstract					
Title	1	D;V	Identify the study as developing and/or validating a multivariable prediction model, the target population , and the outcome to be predicted .	P1/L3	title/Paragraph 1
Abstract	2	D;V	Provide a summary of objectives , study design , setting, participants, sample size, predictors, outcome , statistical analysis , results, and conclusions.	P1-P2/L32-60	abstract/Paragraph 1-4
Introduction					
Background and objectives	3a	D;V	Explain the medical context (including whether diagnostic or prognostic) and rationale for developing or validating the multivariable prediction model, including references to existing models .	P2-P3/L65-100	introduction/Paragraph 1-3
	3b	D;V	Specify the objectives , including whether the study describes the development or validation of the model or both .	P3-P4/L101-103	introduction/Paragraph 3
Methods					
Source of data	4a	D;V	Describe the study design or source of data (e .g ., randomized trial, cohort, or registry data), separately for the development and validation data sets, if applicable .	P4/L107-L121	methods/Paragraph 1
	4b	D;V	Specify the key study dates, including start of accrual; end of accrual; and, if applicable, end of follow-up.	P4/L107-109	methods/Paragraph 1
Participants	5a	D;V	Specify key elements of the study setting (e .g ., primary care, secondary care, general population) including number and location of centres .	P4/L107-108	methods/Paragraph 1
	5b	D;V	Describe eligibility criteria for participants .	P4/L107-115	methods/Paragraph 1
	5c	D;V	Give details of treatments received, if relevant.	N/A	N/A
Outcome	6a	D;V	Clearly define the outcome that is predicted by the prediction model, including how and when assessed.	P4/L107-121	methods/Paragraph 1
	6b	D;V	Report any actions to blind assessment of the outcome to be predicted .	N/A	N/A
Predictors	7a	D;V	Clearly define all predictors used in developing or validating the multivariable prediction model, including how and when they were measured .	P4-P5/L123-L138	methods/Paragraph 2
	7b	D;V	Report any actions to blind assessment of predictors for the outcome and other predictors .	N/A	N/A
Sample size	8	D;V	Explain how the study size was arrived at.	P4/L107-109	methods/Paragraph 1

Missing data	9	D;V	Describe how missing data were handled (e.g., complete-case analysis, single imputation, multiple imputation) with details of any imputation method.	P4/L116-121	methods/Paragraph 1
Statistical analysis methods	10a	D	Describe how predictors were handled in the analyses.	P5/L147-148	methods/Paragraph 4
	10b	D	Specify type of model, all model-building procedures (including any predictor selection), and method for internal validation.	P5/L146-L157	methods/Paragraph 4-5
	10c	V	For validation, describe how the predictions were calculated.	N/A	N/A
	10d	D;V	Specify all measures used to assess model performance and, if relevant, to compare multiple models.	P5/L153-L157	methods/Paragraph 5
	10e	V	Describe any model updating (e.g., recalibration) arising from the validation, if done.	N/A	N/A
Risk groups	11	D;V	Provide details on how risk groups were created, if done.	P5/L146-L157	methods/Paragraph 4-5
Development vs. validation	12	V	For validation, identify any differences from the development data in setting, eligibility criteria, outcome, and predictors.	N/A	N/A
Results					
Participants	13a	D;V	Describe the flow of participants through the study, including the number of participants with and without the outcome and, if applicable, a summary of the follow-up time. A diagram may be helpful.	P5/L161-L168	Results/Paragraph1 Table 1/Paragraph1
	13b	D;V	Describe the characteristics of the participants (basic demographics, clinical features, available predictors), including the number of participants with missing data for predictors and outcome.	P5/L161-L168	Results/Paragraph1 Table 1/Paragraph1
	13c	V	For validation, show a comparison with the development data of the distribution of important variables (demographics, predictors and outcome).	N/A	N/A
Model development	14a	D	Specify the number of participants and outcome events in each analysis.	P5-P6/L161-L178	Results/Paragraph1-2
	14b	D	If done, report the unadjusted association between each candidate predictor and outcome.	N/A	N/A
Model specification	15a	D	Present the full prediction model to allow predictions for individuals (i.e., all regression coefficients, and model intercept or baseline survival at a given time point).	P6/L179-L187	Results/Paragraph3
	15b	D	Explain how to use the prediction model.	P6/L179-L187	Results/Paragraph3
Model performance	16	D;V	Report performance measures (with CIs) for the prediction model.	P6/L189-L194	Results/Paragraph4
Model-updating	17	V	If done, report the results from any model updating (i.e., model specification, model performance).	N/A	N/A
Discussion					
Limitations	18	D;V	Discuss any limitations of the study (such as non representative sample, few events per missing predictor, data).	P9/L273-L276	Discussion/Paragraph7

Interpretation	19a	V	For validation , discuss the results with reference to performance in the development data, and any other validation data .	N/A	N/A
	19b	D;V	Give an overall interpretation of the results, considering objectives, limitations, and results from similar studies, and other relevant evidence .	P7-P9/L205-L276	Discussion/Paragraph2-7
Implications	20	D;V	Discuss the potential clinical use of the model and implications for future research .	P6/L201-L204	Conclusions/Paragraph1
Other information					
Supplementary information	21	D;V	Provide information about the availability of supplementary resources, such as study protocol, Web calculator, and data sets .	N/A	N/A
Funding	22	D;V	Give the source of funding and the role of the funders for the present study .	P9/L284-L285	Funding/Paragraph1

* Items relevant only to the development of a prediction model are denoted by D, items relating solely to a validation of a prediction model are denoted by V, and items relating to both are denoted D;V. We recommend using the TRIPOD Checklist in conjunction with the TRIPOD Explanation and Elaboration document.

Article information: <https://dx.doi.org/10.21037/tp-22-236>

*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.